JP2005525409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525409A5 JP2005525409A5 JP2004500859A JP2004500859A JP2005525409A5 JP 2005525409 A5 JP2005525409 A5 JP 2005525409A5 JP 2004500859 A JP2004500859 A JP 2004500859A JP 2004500859 A JP2004500859 A JP 2004500859A JP 2005525409 A5 JP2005525409 A5 JP 2005525409A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antitumor agent
- agent
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 145
- 229940123237 Taxane Drugs 0.000 claims description 113
- 239000008194 pharmaceutical composition Substances 0.000 claims description 111
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 110
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 claims description 60
- 238000011282 treatment Methods 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 53
- 229940079593 drug Drugs 0.000 claims description 49
- 239000000126 substance Substances 0.000 claims description 32
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 25
- 239000003223 protective agent Substances 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 206010029350 Neurotoxicity Diseases 0.000 claims description 16
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 231100000228 neurotoxicity Toxicity 0.000 claims description 16
- 230000007135 neurotoxicity Effects 0.000 claims description 16
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 16
- 150000003057 platinum Chemical class 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 10
- 238000004904 shortening Methods 0.000 claims description 10
- 206010040021 Sensory abnormalities Diseases 0.000 claims description 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 229960004562 carboplatin Drugs 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 4
- 230000001953 sensory effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000020764 Sensation disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 11
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 8
- 230000002093 peripheral effect Effects 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 231100000862 numbness Toxicity 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 230000006735 deficit Effects 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 230000035807 sensation Effects 0.000 claims 4
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 3
- 208000006820 Arthralgia Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010033799 Paralysis Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims 3
- 229940124444 chemoprotective agent Drugs 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000013372 meat Nutrition 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 208000016285 Movement disease Diseases 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- CETBSQOFQKLHHZ-UHFFFAOYSA-N Diethyl disulfide Chemical compound CCSSCC CETBSQOFQKLHHZ-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010040026 Sensory disturbance Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000004224 protection Effects 0.000 claims 1
- 239000011814 protection agent Substances 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000000694 effects Effects 0.000 description 18
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000011260 co-administration Methods 0.000 description 7
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 4
- 190000008236 carboplatin Chemical group 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940090016 tegretol Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/135,975 | 2002-04-30 | ||
| US10/135,975 US8710095B2 (en) | 2002-04-30 | 2002-04-30 | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| PCT/US2003/013518 WO2003092675A1 (en) | 2002-04-30 | 2003-04-29 | Drugs for mitigating taxane-induced neurotoxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011089619A Division JP2011140521A (ja) | 2002-04-30 | 2011-04-13 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525409A JP2005525409A (ja) | 2005-08-25 |
| JP2005525409A5 true JP2005525409A5 (enExample) | 2008-08-21 |
| JP5416327B2 JP5416327B2 (ja) | 2014-02-12 |
Family
ID=29249584
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500859A Expired - Fee Related JP5416327B2 (ja) | 2002-04-30 | 2003-04-29 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
| JP2011089619A Pending JP2011140521A (ja) | 2002-04-30 | 2011-04-13 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011089619A Pending JP2011140521A (ja) | 2002-04-30 | 2011-04-13 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8710095B2 (enExample) |
| EP (1) | EP1503748B1 (enExample) |
| JP (2) | JP5416327B2 (enExample) |
| AT (1) | ATE554753T1 (enExample) |
| AU (1) | AU2003225253B2 (enExample) |
| CA (1) | CA2483857A1 (enExample) |
| ES (1) | ES2381968T3 (enExample) |
| WO (1) | WO2003092675A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| WO2007070599A2 (en) * | 2005-12-13 | 2007-06-21 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| EP2004175A4 (en) * | 2006-03-16 | 2010-12-15 | Bionumerik Pharmaceuticals Inc | COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE |
| WO2009028605A1 (ja) | 2007-08-31 | 2009-03-05 | Kyushu University, National University Corporation | 抗がん剤による末梢神経障害の予防又は軽減剤 |
| CN101917976B (zh) | 2007-11-20 | 2013-08-28 | 兰肯瑙医学研究所 | 二硫化物化疗药及其在制备癌症治疗的药物中的应用 |
| ES2476602T3 (es) * | 2008-03-14 | 2014-07-15 | Bionumerik Pharmaceuticals, Inc. | Composiciones y métodos quimioprotectores |
| US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| US20090232906A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| DK2249825T3 (en) * | 2008-03-14 | 2016-01-11 | Bionumerik Pharmaceuticals Inc | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| WO2009113989A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| SG10201503402XA (en) | 2010-01-27 | 2015-06-29 | Takeda Pharmaceutical | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent |
| US11471431B2 (en) * | 2010-09-16 | 2022-10-18 | Lantern Pharma Inc. | Increasing cancer patient survival time by administration of dithio-containing compounds |
| ES2796950T3 (es) * | 2013-11-15 | 2020-11-30 | Oncolytics Biotech Inc | Virus oncolíticos y regímenes reforzados para tratamiento de cáncer |
| AU2017384134B2 (en) * | 2016-12-19 | 2022-03-24 | Merck Patent Gmbh | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent |
| EP3440047A4 (en) | 2017-04-17 | 2020-04-01 | Indiana University Research & Technology Corporation | PREVENTING AND REVERSING INFLAMMATION-INSPECTED DNA DAMAGE |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993010076A1 (en) * | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| FR2722987B1 (fr) * | 1994-07-29 | 1997-05-16 | Synthelabo | Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| DE19617802A1 (de) * | 1996-05-03 | 1997-11-06 | Basf Ag | Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen |
| DK0957920T3 (da) | 1996-09-23 | 2002-04-02 | Bionumerik Pharmaceuticals Inc | Reduktion af carboplatins toksiske effekt under anvendelse af dithioethere |
| US6037336A (en) * | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| EP0934261B1 (en) | 1996-10-01 | 2001-10-31 | Bionumerik Pharmaceuticals, Inc. | Process for producing dithiobis-alkanesulfonates and phosphonates |
| US6160167A (en) | 1998-04-21 | 2000-12-12 | Bionumerik Pharmaceuticals, Inc. | Mercaptans and disulfides |
| US6075053A (en) | 1999-02-09 | 2000-06-13 | Bionumerik Pharmaceuticals, Inc. | Method of reducing or reversing neuropathy |
| US5998479A (en) | 1999-02-09 | 1999-12-07 | Bionumerik Pharmaceuticals, Inc. | Method of treating adult respiratory syndrome |
| US6197831B1 (en) | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
| US6172119B1 (en) | 1999-02-09 | 2001-01-09 | Bionumerik Pharmaceuticals, Inc. | Method of treating acute renal failure |
| US6177411B1 (en) | 1999-02-09 | 2001-01-23 | Bionumerik Pharmaceuticals, Inc. | Method for treating heavy metal poisoning |
| US6034126A (en) | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
| US6077838A (en) | 1999-06-08 | 2000-06-20 | Bionumerik Pharmaceuticals, Inc. | Method of treating hangover |
| US6143796A (en) | 1999-09-02 | 2000-11-07 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of free radical induced malignancies |
| US6468993B1 (en) | 1999-10-04 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of osteoporosis |
| US6043274A (en) | 1999-10-21 | 2000-03-28 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic cardiomyopathy |
| US6251881B1 (en) | 1999-10-21 | 2001-06-26 | Frederick H. Hausheer | Method of treating diabetic angiopathy |
| US6031006A (en) | 1999-10-21 | 2000-02-29 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic nephropathy |
| US6100247A (en) | 1999-10-21 | 2000-08-08 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic neuropathy |
| US6274622B1 (en) | 1999-10-27 | 2001-08-14 | Frederick H. Hausheer | Method of treating diabetic ophthalmopathy |
| US6525037B1 (en) | 2000-02-25 | 2003-02-25 | Bionumerik Pharmaceuticals, Inc. | Method of treating atherosclerosis and complications resulting therefrom |
| AU2000239101A1 (en) * | 2000-03-22 | 2001-10-03 | Neopharm, Inc. | A method of administering liposomal encapsulated taxane |
| US6245815B1 (en) | 2000-04-15 | 2001-06-12 | Bionumerik Pharmaceuticals, Inc. | Method of treating alcoholism and complications resulting therefrom |
| US6468963B1 (en) | 2000-05-01 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Methods and formulations for reducing toxicity associated with diabetes treatments |
| FR2811987A1 (fr) | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
| US6225295B1 (en) | 2000-09-27 | 2001-05-01 | Frederick H. Hausheer | Method of treating acetaminophen overdose |
| US6291441B1 (en) | 2000-09-27 | 2001-09-18 | Frederick H. Hausheer | Method of treating inflammatory bowel disorders |
| US6255355B1 (en) | 2001-01-06 | 2001-07-03 | Seetharamulu Peddaiahgari | Method of inhibiting angiogenesis |
| WO2002056755A2 (en) | 2001-01-19 | 2002-07-25 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer |
| US6352979B1 (en) | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
| US7176192B2 (en) | 2001-10-26 | 2007-02-13 | Bionumerik Pharmaceuticals, Inc. | Method for treating patients for radiation exposure |
| US6596320B1 (en) * | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US6504049B1 (en) | 2002-04-30 | 2003-01-07 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing pharmaceutically active disulfide salts |
| US20040014730A1 (en) | 2002-07-10 | 2004-01-22 | Frederick Hausheer | Formulations and methods of reducing toxicity of anti-infective agents |
| AU2002360747B2 (en) | 2002-12-21 | 2008-07-03 | Bionumerik Pharmaceuticals, Inc. | Method of treating patients exposed to toxic chemical agents |
| US20040152774A1 (en) | 2003-02-04 | 2004-08-05 | Hausheer Frederick H. | Method of protecing against tissue extra vasation injury |
| AU2004299131B2 (en) | 2003-12-17 | 2010-05-13 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing disulfides |
-
2002
- 2002-04-30 US US10/135,975 patent/US8710095B2/en not_active Expired - Fee Related
-
2003
- 2003-04-29 AT AT03721972T patent/ATE554753T1/de active
- 2003-04-29 CA CA002483857A patent/CA2483857A1/en not_active Abandoned
- 2003-04-29 WO PCT/US2003/013518 patent/WO2003092675A1/en not_active Ceased
- 2003-04-29 ES ES03721972T patent/ES2381968T3/es not_active Expired - Lifetime
- 2003-04-29 AU AU2003225253A patent/AU2003225253B2/en not_active Ceased
- 2003-04-29 EP EP03721972A patent/EP1503748B1/en not_active Expired - Lifetime
- 2003-04-29 JP JP2004500859A patent/JP5416327B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-13 JP JP2011089619A patent/JP2011140521A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
| US8518930B2 (en) | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent | |
| CN100411628C (zh) | 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用 | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| CA2386876A1 (en) | Combination chemotherapy | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| EP1273296B1 (en) | Combination of acetyldinaline and docetaxel | |
| HRP20030382A2 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| JP2019131508A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| Ajani et al. | Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma | |
| Castro et al. | 4CPS-105 Prescribed antineoplastic agents in paediatric patients | |
| US20030134893A1 (en) | Combination chemotherapy | |
| Agelaki et al. | A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer | |
| Gleason et al. | 18 neuropathy in plasma cell disorders | |
| WO2004073719A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
| Gleason et al. | Treatment of emergent peripheral neuropathy in plasma cell disorders | |
| TW201306832A (zh) | 用於治療骨髓發育不良症候群的組成物及方法 |